Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FDL176 in Healthy and Cystic Fibrosis Participants
NCT03173573Phase 1Completed
- Sponsor
- Flatley Discovery Lab
- Start
- Jun 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FDL176 in cystic fibrosis (CF) (9 arms), sponsored by Flatley Discovery Lab. Primary endpoints: Treatment-Emergent Adverse Events at 6 weeks, Maximum Plasma Concentration at 5 weeks and 4 more. Started Jun 2017; status: completed.
02
Drugs
FDL176
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03173573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173573.